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Failure to Detect Linkage of Preeclampsia to the
Region of the NOS3 Locus on Chromosome 7q
To the Editor:
Preeclampsia is an important inheritable pregnancy-re-
lated hypertension syndrome. Since it develops as a result
of widespread endothelial dysfunction, the NOS3 gene
responsible for endothelium-derived nitric oxide (NO)
production via its gene product, eNOS, has been sug-
gested as an obvious candidate gene for preeclampsia
(Morris et al. 1996). We were intrigued, therefore, by
the report, by Arngrı´msson et al. (1997), of linkage in
the region of the NOS3 gene and have attempted to
repeat their findings in our own collection of preeclamp-
sia families.
Evidence for linkage was sought by use of two, sep-
arately ascertained, affected sister-pairs (ASPs) collec-
tions, from Amsterdam and Cambridge (United King-
dom), that contained 104 sibships. In the Cambridge
Centre, a total of 21 extended pedigrees were also iden-
tified, some on the basis of the ASPs suitable for con-
ventional parametric linkage studies. All affected indi-
viduals were Caucasian and met the Redman and
Jefferies criteria of preeclampsia: they were proteinuric
(1300 mg/24 h) and hypertensive, with a blood pressure
of 1140/90 occurring after 20-wk gestation and with a
25-mmHg rise in diastolic blood pressure (Redman
and Jefferies 1988). These features all resolved by 3 mo
postpartum, and none of the subjects had concurrent
diabetes, renal disease, or essential hypertension. Some
sibships (!5%) contained subjects showing features of
pregnancy-induced hypertension (PIH) alone (i.e., they
were not proteinuric). These members were not included
in subsequent sib-pair analysis, and none of the larger
pedigrees used contained subjects with PIH. For the pur-
poses of linkage analysis, all males were assigned to the
affection status of “unknown.”
Subjects were genotyped for the CA-repeat marker
within intron 13 of the NOS3 gene (referred to here as
“NOS3i13”). The Cambridge samples were also geno-
typed for the two flanking markers D7S483 and
D7S505. Genotyping was performed by use of PCR am-
plification of the microsatellite markers by means of
primer pairs, in which the forward primer had been 5′
end–labeled with a fluorescent amidite. CEPH primer
sequences were used for the flanking markers, and
primer sequences published elsewhere were used for
NOS3i13 (Nedaud et al. 1994). The PCR products were
multiplexed and were run on an ABI 377, and allele
sizes were determined by use of version 2 of GENO-
TYPER (Applied Biosystems).
The number of alleles shared identical by descent
(IBD) was calculated for the ASPs by use of the maxi-
mum-likelihood method, as implemented in SPLINK
(Holmans 1993; Holmans and Clayton 1995). Parental
genotype data were used where available but were in-
complete for the Cambridge ASPs and were not available
for the Amsterdam ones. Comparison of allele frequen-
cies and marker heterozygosity from the SPLINK output
for the two groups showed no significant differences
between the two collections. The allele sharing for the
NOS3i13 marker is shown in table 1, for both the Am-
sterdam and Cambridge ASPs. There is no evidence of
excess allele sharing in either group. In fact, the Cam-
bridge group shows a deficit of allele sharing, attribut-
able to chance alone. To confirm this, allele sharing for
the two flanking markers for NOS3, D7S483 and
D7S505, was investigated. These two flanking markers
are approximately equidistant from NOSi13 and span
a 4-cM region over 7q36. Again, there was no evidence
of a significant positive deviation from a 1:2:1 distri-
bution in the Cambridge group, either for D7S483 or
for D7S505.
Parametric analysis of the preeclampsia pedigrees was
performed by use of four of the models, employed else-
where (Arngrı´msson et al. 1997), as follows (q is the
frequency of disease gene, and f is the penetrance): an
autosomal model (AD) of high arbitrary penetrance
( , ), a partial-dominance model (AD/LP;q  .02 f  0.9
, , ), a fully recessive modelq  .10 f  0.21 f  1.0Aa AA
(AR; ), and an affecteds-only model (AO;q  .2 q 
, ). The power of the preeclampsia.02 f  f  0.001Aa AA
pedigree collection to detect linkage was estimated by
means of simulation of each model, by use of SLINK
(Weeks et al. 1991; Ott 1989). The results of 500 rep-
lications of each model generated by SLINK, if a hy-
pothetical marker with eight equally frequent alleles
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Table 1
Allele Sharing for NOS3i13 and Flanking Markers
ASP COLLECTION
AND MARKER
NO. OF ALLELES
SHARED IBD
P0 1 2
Amsterdam ( ):n  46
NOS3i13 11.1 20.2 14.6 .250
Cambridge ( ):n  58
D7S483 11.3 32.0 14.7 .388
NOS3i13 18.0 28.0 12.0 .584
D7S505 15.1 30.0 13.8 .584
Combined ( ):n  104
NOS3i13 28.9 47.8 26.3 .547
Table 2
Results of Computer Simulations with SLINK, for 500 Replicates
MODEL
AVERAGE LOD SCORE AT v 
.0 .1 .2 .3 .4
AD 6.05 4.89 3.37 1.92 .75
AD/LP 1.70 1.49 .99 .53 .18
AR 4.89 3.81 2.48 1.26 .39
AO 3.88 3.12 2.05 1.08 .37
( ) is assumed, are summarized in tables 2 andPIC  .86
3. These results show that such a marker linked tightly
to preeclampsia provides an average LOD score suffi-
cient to establish linkage in three of the four models.
The power of the simulated marker to detect linkage in
the AD/LP model is substantially less than that of the
other three models, as has been noted elsewhere (Har-
rison et al. 1997).
The models were tested by use of all three markers
for the 4-cM interval, on 7q, encompassing the NOS3
locus. Table 4 shows the results of two-point linkage
analysis, using allele frequencies provided by SPLINK;
the findings were not altered significantly by the assign-
ment of equal allele frequencies throughout. For all the
models, linkage to NOS3i13 could be excluded with
. As expected from the SLINK modeling, theLOD ! 2
low-penetrance AD/LP model provided smaller LOD
scores than did the other three models, and linkage to
the flanking markers could not be excluded in our pre-
eclampsia pedigrees. However, for neither of themarkers
under the AD/LP model did the LOD scores approach
the required threshold of (Kidd and Ott3 log (4)
1984).
These results, therefore, have failed to confirm linkage
of preeclampsia to a chromosome 7q 4-cM region con-
taining the NOS3 gene, as reported by Arngrı´msson et
al. (1997). This failure occured despite use of a similar
combination of ASPs and conventional two-point link-
age in pedigrees. Our study used two independently as-
certained collections of ASPs, containing a total of 104
ASPs that appeared to be powered adequately. We have
estimated the ls for preeclampsia at ∼10, assuming a
local prevalence of preeclampsia (using our strict defi-
nition) of some 2%. Since our total ASP collection con-
tains 70 fully informative pairs (estimated by SPLINK)
for the NOSi13 marker, an expected maximized LOD
score of 7.6 is given (Risch 1990). Even if ls has been
overestimated, a figure of 5 would still result in a LOD
score substantially 13 (actually 5.7).
Our inability to replicate the earlier linkage report
could reflect population differences, although both stud-
ies are based on white northern Europeans. It is possible
that significant differences in our definition of the pre-
eclampsia phenotype may be important, although the
differences in our method of ASP analysis seem unlikely.
We have focused in our study only on ASPs with a def-
inite diagnosis of preeclampsia, excluding ones in which
the diagnosis either is uncertain or is consistent onlywith
isolated PIH. Nevertheless, Arngrı´msson et al. (1997)
report that the significance of the excess allele sharing
was not substantially altered by removal of the milder
phenotypes from the sib-pair analysis. Our method of
sib-pair analysis relies on amaximum-likelihoodmethod
(SPLINK) to calculate allele sharing that is IBD. The
SPLINK program is able to utilize parental genotype
data, although this was not available for most of our
ASPs. The previous linkage study on 7q also used a
likelihood ratio–based method (SIBPAIR), as well as di-
rect testing of increased identity by state (IBS) sharing
(APM). A recent comparison of the various methods
available to detect linkage in nuclear pedigrees, including
sib pairs, showed the superiority of IBD-based programs
versus IBS-based programs (Davis and Weeks 1997). In
this comparison, SPLINK actually showed comparable
power to detect linkage with the SIBPAIR program, ex-
cept when additional genotypes were available from un-
affected members, which was not the case in this study.
Our choice of SPLINK, therefore, is unlikely to have
increased the possibility of a false-negative result.
The previous positive sib-pair analysis reported by
Arngrı´msson’s group was also supported by two-point
linkage results from their pedigree collection (Arngrı´ms-
son et al. 1997). They investigated a number of different
models, reported elsewhere, from the literature. The
LOD score, maximized over the five models, was 4.03,
by use of the D7S505 flanking marker rather than the
NOS3i13 marker. This suggests that the preeclampsia
locus may be some distance away from the NOS3 gene
itself, although theNOS3i13marker and the preeclamp-
sia locus must be in linkage disequilibrium, on the basis
of their transmission/disequilibrium-test results. Adopt-
ing a similar parametric analysis in our own preeclamp-
sia pedigrees, we have failed to demonstrate a LOD score
high enough to confirm linkage in any of the models. In
fact, the LOD scores generated actually have enabled us
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Table 3
Results of Two-Point Linkage Analysis
MODEL
% OF REPLICATES WITH
LOD-SCORE THRESHOLD 1
1 2 3
AD 100.0 99.4 97.6
AD/LP 78.4 41.4 10.8
AR 100.0 98.4 89.2
AO 98.8 89.6 72.4
to exclude linkage in all of them, except the AD/LP
model. Using the AD/LP model, we did find a small,
nonsignificant LOD score, using a flanking marker, but
it was by use of D7S483 and not D7S505—that is, at
the opposite end of the 7q interval.
A key role for endothelium-derived NO in pregnancy
is well supported. An eNOS inhibitor, for example, in-
fused chronically into pregnant animals, produces a
preeclampsia-like state, with hypertension, proteinuria,
thrombocytopenia, and growth retardation (Molnar and
Hertelendy 1992). More-recent findings also provide di-
rect evidence for the role of NO production in the fall
in peripheral vascular resistance (and blood pressure)
seen in normal human pregnancy (Knock and Poston
1996). It is possible that NO forms part of an adaptation
pathway, to accommodate the cardiovascular changes of
pregnancy and to prevent the development of maternal
hypertension and the clinical syndrome of preeclampsia.
However, although these data provide a tantalizing cir-
cumstantial argument for NOS3 being a candidate gene
for preeclampsia, they do not prove that a primary ab-
normality in eNOS underlies the pathophysiology of pre-
eclampsia. It is equally plausible that the observed
changes in NO production during preeclampsia are
secondary to free-radical damage of the vascular
endothelium.
In summary, then, we have been unable to replicate
the previous report of linkage of preeclampsia to the
region of theNOS3 gene. Although abnormalities inNO
production have been observed in preeclampsia, we be-
lieve that the case for the NOS3 gene or its product,
eNOS, having a primary role in the pathophysiology of
preeclampsia remains unproved.
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Table 4
Two-Point Linkage Results for the Four Models Tested
MODEL AND
MARKER
LOD SCORE AT v 
.00 .01 .05 .10 .20 .30 .40
AD:
D7S505 7.22 5.52 3.01 1.59 .34 .08 .14
NOS3i13 9.76 8.40 5.41 3.44 1.40 .46 .07
D7483 2.37 2.05 1.27 .80 .41 .26 .15
AD/LP:
D7S505 1.56 1.40 .90 .49 .07 .07 .07
NOS3i13 2.08 1.86 1.20 .67 .12 .07 .08
D7483 .34 .39 .51 .53 .39 .17 .02
AR:
D7S505  7.02 3.63 2.08 .74 .23 .04
NOS3i13  7.69 3.98 2.16 .58 .04 .07
D7483  3.80 1.46 .50 .11 .14 .03
AO:
D7S505 3.20 2.51 1.03 .22 .32 .34 .20
NOS3i13 6.03 5.05 2.92 1.63 .47 .06 .04
D7483 1.91 1.59 .86 .43 .13 .09 .08
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